Name | GSK-872 |
---|---|
Synonyms |
4-Quinolinamine, N-5-benzothiazolyl-6-[(1-methylethyl)sulfonyl]-
N-(1,3-Benzothiazol-5-yl)-6-(isopropylsulfonyl)-4-quinolinamine GSK'872 |
Description | GSK'872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. |
---|---|
Related Catalog | |
Target |
RIPK3[1] |
In Vitro | GSK'872 blocks necroptosis in mouse cells. RIP3i GSK'872 inhibits TLR3- or DAI-induced death, two RIP1-independent pathways of necroptosis[1]. Pretreatment with GSK'872 (GSK-872) confers significant protection to primary hepatocytes. However, RIPK1 inhibition (by Nec1) does not impart any protection to primary hepatocytes[2]. |
Cell Assay | Cell viability is estimated by Trypan blue exclusion and MTT assay. Treatment of inhibitors [N-acetyl Cysteine (NAC), butylated hydroxyanisole (BHA), IM54, Bay11-7082, Z-VAD-FMK, caspase-8 inhibitor, GSK'872 (200 nM) and necrostatin-1 (Nec-1)] is given for 4 h before Deltamethrin (DLM) treatment[2]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 625.7±55.0 °C at 760 mmHg |
Molecular Formula | C19H17N3O2S2 |
Molecular Weight | 383.487 |
Flash Point | 332.2±31.5 °C |
Exact Mass | 383.076202 |
LogP | 3.10 |
Vapour Pressure | 0.0±1.8 mmHg at 25°C |
Index of Refraction | 1.704 |
Storage condition | -20℃ |